Overview

Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma

Status:
Active, not recruiting

Trial end date:
2023-05-11

Target enrollment:

Participant gender:

Summary

The study will evaluate the clinical activity of sitravatinib in combination with nivolumab in patients with locally-advanced clear cell renal cell carcinoma (ccRCC) in the neoadjuvant setting prior to nephrectomy.

Phase:

Phase 2

Details

Lead Sponsor:

Mirati Therapeutics Inc.

Treatments:

Nivolumab